Literature DB >> 18165917

Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid.

Gunfer Turgut1, Erhan Kurt, Cem Sengul, Gazi Alatas, Raziye Kursunluoglu, Timucin Oral, Sabahat Turgut, Hasan Herken.   

Abstract

P-glycoprotein (P-gp), an efflux transporter protein, is an ABC transporter encoded by the multidrug resistance 1 gene (MDR1, ABCB1). The common synonymous C3435T polymorphism in exon 26 is reported to associate with lower P-gp functional expression and drug uptake. Many extended pharmacogenomics, functional, and complex disease association studies focused mainly on this polymorphism. We investigated the association of exon 26 C3435T genetic variants of MDR1 gene with susceptibility to bipolar disorder and serum valproic acid concentration. Totally, 104 patients meeting DSM-IV criteria for bipolar disorder and 169 controls were admitted to the study. There was statistically significant difference between the genotypes of bipolar patients (CT 91.2%, TT 6.8%, and CC 2%) and controls (CT 52.7%, TT 26%, CC 21.3%) although their allelic distribution was similar. The serum valproic acid concentrations of the patients with CT, TT and CC genotypes were 72.92 +/- 20.55, 80.47 +/- 14.01 and 68.29 +/- 12.17 microg/ml, respectively, and there was no significant difference between the C3435T genotypes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18165917     DOI: 10.1007/s11033-007-9206-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  32 in total

Review 1.  The corticosteroid receptor hypothesis of depression.

Authors:  F Holsboer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.

Authors:  Nada Bozina; Martina Rojnic Kuzman; Vesna Medved; Nikolina Jovanovic; Jadranka Sertic; Ljubomir Hotujac
Journal:  J Psychiatr Res       Date:  2006-11-20       Impact factor: 4.791

3.  In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

Authors:  David W Boulton; C Lindsay DeVane; Heidi L Liston; John S Markowitz
Journal:  Life Sci       Date:  2002-05-31       Impact factor: 5.037

Review 4.  Valproate in bipolar disorder: 2000 onwards.

Authors:  C L Bowden; V Singh
Journal:  Acta Psychiatr Scand Suppl       Date:  2005

5.  Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.

Authors:  Norio Yasui-Furukori; Manabu Saito; Taku Nakagami; Ayako Kaneda; Tomonori Tateishi; Sunao Kaneko
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-01-04       Impact factor: 5.067

6.  Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

Authors:  Norio Yasui-Furukori; Kazuo Mihara; Takenori Takahata; Akihito Suzuki; Taku Nakagami; Ronald De Vries; Tomonori Tateishi; Tsuyoshi Kondo; Sunao Kaneko
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 7.  P-glycoprotein, multidrug resistance and tumor progression.

Authors:  G Bradley; V Ling
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 8.  Clinical aspects of the MDR1 (ABCB1) gene polymorphism.

Authors:  Michel Eichelbaum; Martin F Fromm; Matthias Schwab
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

9.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

Authors:  Taku Furuno; Maria-Teresa Landi; Mauro Ceroni; Neil Caporaso; Ilaria Bernucci; Giuseppe Nappi; Emilia Martignoni; Elke Schaeffeler; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenetics       Date:  2002-10

Review 10.  Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Authors:  Catia Marzolini; Erik Paus; Thierry Buclin; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2004-01       Impact factor: 6.875

View more
  6 in total

1.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  The pharmacogenomics of valproic acid.

Authors:  Miao-Miao Zhu; Hui-Lan Li; Li-Hong Shi; Xiao-Ping Chen; Jia Luo; Zan-Ling Zhang
Journal:  J Hum Genet       Date:  2017-09-07       Impact factor: 3.172

Review 3.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

4.  Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia.

Authors:  Takahiro Shinkai; Vincenzo De Luca; Kensuke Utsunomiya; Shinichi Sakata; Yoshiaki Inoue; Yuko Fukunaka; Rudi Hwang; Osamu Ohmori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

Review 5.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

Review 6.  Blood-brain barrier dysfunction in bipolar disorder: Molecular mechanisms and clinical implications.

Authors:  Ning O Zhao; Natasha Topolski; Massimo Tusconi; Erika M Salarda; Christopher W Busby; Camila N N C Lima; Anilkumar Pillai; Joao Quevedo; Tatiana Barichello; Gabriel R Fries
Journal:  Brain Behav Immun Health       Date:  2022-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.